Abstract: Described are novel anti-CTLA-4 antibody molecules and nucleotide sequences and expression vectors, such as viruses, encoding such antibody molecules. The novel antibody molecules are Treg depleting antibody molecules, and they have an improved depleting effect on CTLA-4 positive cells, such as Tregs, compared to ipilimumab. Described is also the use of such antibody molecules or nucleotide sequences or viruses in medicine, such as in the treatment of cancer, such as solid tumours.

Abstract: A method for detecting characteristic cells in a sample includes performing a first lysis of a sample to yield a first lysate wherein nuclei of the cells of the sample remain intact. Freely available RNA in the first lysate is extracted and classified to ascertain the amounts of various types of RNA in the first lysate. A second lysis operation on the previously lysed sample is performed to yield a second lysate wherein the cell nuclei of the cells in the sample are destroyed. DNA freely available in the second lysate is extracted and a total cell count of cells in the provided sample is calculated on the basis of the amount of extracted DNA. The number of cells having individual cell markers in the provided sample is calculated using the ascertained amounts of various types of RNA and the calculated total cell count.

Abstract: The present disclosure provides compositions comprising antigen binding polypeptides. More particularly, the disclosure relates to polypeptides comprising antibodies or antigen binding fragments thereof, nucleic acids encoding the polypeptides, and vectors for expressing the same.

Abstract: Provided are anti-PD-1 antibodies or fragments thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer, infection or immune disorders are also provided.

Abstract: The invention in suitable embodiments is directed to dynamic bio-nanoparticle elements and bio-nanoparticle platforms employing such bio-nanoparticle elements. In one aspect, one or more elements of one or more types, formed from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more types of Clathrin and or Coatomer I/II proteins of one or more isoforms, execute one or more functions and or effect one or more ends, in vivo and or in vitro.

Abstract: A process for producing products containing organic salts from biodegradable feedstocks includes fermenting biodegradable feedstock using natural consortia of microorganisms to produce a first product stream including carboxylic acid salts, suspended solids and water; removing suspended solids from the first product stream to produce a second product stream including carboxylic acid salts; concentrating the second product stream to produce a third product stream and water; and further drying the third product stream to remove water and produce a fourth product stream including dry carboxylic acid salts.

Abstract: A temperature-sensitive cell culture composition is provided. The temperature-sensitive cell culture composition includes a hydrogel, a cellulose, a gelatin and a collagen. Based on 1 part by weight of the collagen, a content of the hydrogel is between 0.03 parts by weight and 60 parts by weight, a content of the cellulose is between 150 parts by weight and 360 parts by weight, and a content of the gelatin is between 21 parts by weight and 12 parts by weight. In addition, a method for using the temperature-sensitive cell culture composition, a method for forming the temperature-sensitive cell culture composition, and a use of the temperature-sensitive cell culture composition are also provided.

Abstract: Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing enzymes or enzyme domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing enzymes or domains, are provided.

Abstract: This application provides improved methods of genome editing. Cas9 molecules can be used to create a break in a genomic region of interest. To increase the likelihood that the break is repaired by HDR (homology-directed repair), the cell can be contacted with molecules that bring a template nucleic acid in close proximity to the break, under conditions that allow the cell to repair the break using the template nucleic acid.

Abstract: Disclosed are a deer-derived specific peptide and a detection method therefor; by screening through a large number of experiments, a ratio of relative contents of two deer-derived peptides is determined, and a graph is drawn by using a proportion of a deer antler gelatin in a mixed gelatin as an abscissa and using a value of Apeptide 1/Apeptide 2 as an ordinate; the proportion of the deer antler gelatin is linear with Apeptide 1/Apeptide 2 as a standard curve equation to distinguish a deer hide gelatin from the deer antler gelatin; the method can be used for distinguishing the deer antler gelatin from the deer hide gelatin, and controlling the quality; a defect in the prior art that the deer antler gelatin and the deer hide gelatin are difficult to distinguish in appearance, and are also difficult to distinguish by using a specific peptide fragment, is solved.

Abstract: Provided are peptides, and conjugates comprising targeting peptides and payloads. The peptides comprise a plurality of modules corresponding to at least one of module 1, module 2, or module 3 of the collagen binding domain of a gelatinase, or a gelatin-binding fragment or variant thereof. The gelatinase may be MMP-2. The conjugates may be therapeutic or non-therapeutic. Medical uses of the peptides or therapeutic conjugates, and pharmaceutical compositions comprising these, are also provided, as are nucleic acids encoding the peptides.

Abstract: The present specification discloses a urate oxidase-albumin conjugate, a preparation method thereof, a urate oxidase variant contained in the urate oxidase-albumin conjugate, and a preparation method thereof. The urate oxidase-albumin conjugate is characterized in that three or more albumins are conjugated to the urate oxidase variant through a linker, thereby improving half-life and reducing immunogenicity. In addition, the urate oxidase-albumin conjugate can be used to prevent or treat various diseases, disorders and/or indications caused by uric acid.

Abstract: The present disclosure provides a drug carrier, a brain-targeting nanodrug based on CRISPR gene editing technology and a preparation method and use thereof. The nanodrug contains nanoparticles prepared by coupling Cas9/sgRNA and drug carriers. The drug carrier includes a polymer mPEG-P (GPMA, FPMA) and a polymer Ang-PEG-PGPMA, wherein a structural formula of the mPEG-P (GPMA, FPMA) is: a structural formula of the polymer Ang-PEG-PGPMA is: where n is 35-45, x1 is 15-20, y is 2-4, m is 75-85, and x2=x1. The guanidino group of the drug carrier can be combined with the ribonucleoprotein complex by electrostatic action, salt bridge formation, or hydrogen bonding action. Also provided are methods of suppressing and treating tumors at a gene level using the drug carrier to transport the therapeutic drug to the lesion site.

Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

Abstract: The present disclosure provides intrabody compositions comprising i) an intrabody and ii) one or more inserts. The disclosure also provides methods for activating and deactivating intracellular and extracellular interactions utilizing the compositions, for instance via chemical and/or light.

Abstract: The present disclosure provides various insights relating to treatment of viral infection with soluble ACE2 variants, specifically including soluble human ACE2 (hACE2) variants. For example, the present disclosure teaches that decoy activity, which may intercept virus-receptor interactions, and ACE2 enzymatic activity can provide separate contributions to therapeutic efficacy; among other things, the present disclosure provides particular therapeutic regimens (e.g., relating to treatment of particular patient populations and/or to dosing regimens, combination therapies, etc.) for certain soluble ACE2 variants. Still further, the present disclosure provides certain particular ACE2 variants and methods of making and/or using them, including in accordance with particular therapeutic regimens.

Abstract: Compositions and methods for darkening hair of intact skin are presented. Such compositions include defensins in concentrations that are below those that exhibit antimicrobial activity, and can be in the form of a topically applied formulation. Various formulations for such compositions, which can include various pharmaceutically acceptable stabilizers, emollients, and fragrances, are provided.

Abstract: The present invention relates to conjugation-competent albumins and albumin-related polypeptides, and their conjugates with at least one moiety, and to polynucleotides encoding them.

Abstract: In various aspects, the present disclosure pertains to sorbents for isolating at least one target protein from a liquid sample, the sorbents comprising a solid support comprising attached at least one attached high affinity reagent with an affinity for the at least one target protein. Other aspects of the present disclosure include kit that contain such sorbents and methods of treating samples using the same.

Abstract: A coat protein of Junonia coenia densovirus (JcDNV) is used to deliver attached peptide insect toxin across the gut epithelium of a fall armyworm, Spodoptera frugiperda. A fusion protein comprising VP4 attached to an insect toxin via a peptide linker is developed. A composition comprising a JcDNV coat protein attached to an insect toxin via a peptide linker can be used for insect pest control.